Major trial launches to test mpox vaccine in african outbreak zone
NCT ID NCT07093489
Summary
This study aims to find out how well and how safe the LC16m8 vaccine is at preventing mpox (monkeypox) in the Democratic Republic of Congo, where outbreaks are happening. It will involve nearly 12,000 people aged one year and older. Researchers will compare people who get sick with mpox to those who don't, to see if vaccination made a difference, and will closely monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Institut National de la Recherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.